3-[2-[4-(3,4-dimethylphenyl)-1-piperazinyl]ethyl]-2,3-dihydro-1H-isoindol-1-onedihydrochloride
![3-[2-[4-(3,4-dimethylphenyl)-1-piperazinyl]ethyl]-2,3-dihydro-1H-isoindol-1-onedihydrochloride Structure](https://image.chemsrc.com/caspic/137/210688-56-5.png)
3-[2-[4-(3,4-dimethylphenyl)-1-piperazinyl]ethyl]-2,3-dihydro-1H-isoindol-1-onedihydrochloride structure
|
Common Name | 3-[2-[4-(3,4-dimethylphenyl)-1-piperazinyl]ethyl]-2,3-dihydro-1H-isoindol-1-onedihydrochloride | ||
|---|---|---|---|---|
| CAS Number | 210688-56-5 | Molecular Weight | 422.39100 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C22H29Cl2N3O | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of 3-[2-[4-(3,4-dimethylphenyl)-1-piperazinyl]ethyl]-2,3-dihydro-1H-isoindol-1-onedihydrochloridePD 168568 is a orally active and potent dopamine receptor D4 (DRD4) antagonist. PD 168568 contains an isoindolinone and is selective for the D4 receptor versus D2 and D3, with Ki values of 8.8, 1842, and 2682 nM, respectively. PD 168568 can be used for glioblastoma (GBM) research[1][2]. |
| Name | 3-[2-[4-(3,4-dimethylphenyl)piperazin-1-yl]ethyl]-2,3-dihydroisoindol-1-one,dihydrochloride |
|---|
| Description | PD 168568 is a orally active and potent dopamine receptor D4 (DRD4) antagonist. PD 168568 contains an isoindolinone and is selective for the D4 receptor versus D2 and D3, with Ki values of 8.8, 1842, and 2682 nM, respectively. PD 168568 can be used for glioblastoma (GBM) research[1][2]. |
|---|---|
| Related Catalog | |
| Target |
D4 Receptor:8.8 nM (Ki) D2 Receptor:1842 nM (Ki) D3 Receptor:2682 nM (Ki) |
| In Vitro | PD 168568 对胶质母细胞瘤神经干细胞 (GNS) 表现出选择性抑制，IC50 为 25-50 µM[1]。 |
| In Vivo | PD 168568 (3 mg/kg，口服) 可抑制大鼠 amphetamine 刺激的运动活动[3]。 Animal Model: Rat[1] Dosage: 3 mg/kg Administration: Oral administration Result: Inhibited amphetamine (0.5 mg/kg, i.p.) stimulated locomotor activity. |
| References |
| Molecular Formula | C22H29Cl2N3O |
|---|---|
| Molecular Weight | 422.39100 |
| Exact Mass | 421.16900 |
| PSA | 35.58000 |
| LogP | 5.23590 |
|
~58%
3-[2-[4-(3,4-di... CAS#:210688-56-5 |
| Literature: Warner-Lambert Company Patent: US6087364 A1, 2000 ; US 6087364 A |
|
~%
3-[2-[4-(3,4-di... CAS#:210688-56-5 |
| Literature: Belliotti, Thomas R.; Brink, Wouter A.; Kesten, Suzanne R.; Rubin, John R.; Wustrow, David J.; Zoski, Kim T.; Whetzel, Steven Z.; Corbin, Ann E.; Pugsley, Thomas A.; Heffner, Thomas G.; Wise, Lawrence D. Bioorganic and Medicinal Chemistry Letters, 1998 , vol. 8, # 12 p. 1499 - 1502 |
|
~%
3-[2-[4-(3,4-di... CAS#:210688-56-5 |
| Literature: Warner-Lambert Company Patent: US6087364 A1, 2000 ; US 6087364 A |
|
~%
3-[2-[4-(3,4-di... CAS#:210688-56-5 |
| Literature: Warner-Lambert Company Patent: US6087364 A1, 2000 ; US 6087364 A |
|
~%
3-[2-[4-(3,4-di... CAS#:210688-56-5 |
| Literature: Warner-Lambert Company Patent: US6087364 A1, 2000 ; US 6087364 A |
|
~%
3-[2-[4-(3,4-di... CAS#:210688-56-5 |
| Literature: Belliotti, Thomas R.; Brink, Wouter A.; Kesten, Suzanne R.; Rubin, John R.; Wustrow, David J.; Zoski, Kim T.; Whetzel, Steven Z.; Corbin, Ann E.; Pugsley, Thomas A.; Heffner, Thomas G.; Wise, Lawrence D. Bioorganic and Medicinal Chemistry Letters, 1998 , vol. 8, # 12 p. 1499 - 1502 |
